Three Steps to Boost Asymchem's Investment in China
TIANJIN, China, Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China's
leading CMO companies, announced today the Company's investment and
expansion plans in China. Apart from new plants and R & D facility, the
Company will also invest heavily in training and form strategic alliances
in the near future.
(Photo:
http://www.newscom.com/cgi-bin/prnh/20071227/CNTH002 )
I. Quality Facilities: New cGMP Pilot Plant and R&D Building became
Operational in October, 2007
The new Asymchem Life Science (Tianjin) Co., Ltd site began operation
with the opening of its new cGMP Pilot Plant in October 2007 and projected
opening of a new R&D Building 1Q 2008. The initial investment for the site
to date is 180 million RMB, with further construction on-going for
completion in late 2008.
凯莱英在天津总投资额为4亿8千万人民币。
A total investment of 480 million RMB has been allotted for the 100,000
sqm site located in TEDA, Tianjin, one of the more prestigious high tech
parks in China. Asymchem will build cGMP production facilities following
ICH Q7A guidelines. Supporting facilities at this site will include an R&D
center, an analytical research center and an EHS center that follow
international standards. The goal is to achieve comprehensive facilities
for development and production of cGMP intermediates and APIs at kilogram
to mton scale. In the end, Asymchem will be in position to provide a
variety of advanced technical services for pharmaceutical and biotech
companies.
Phase I construction of Asymchem Life Science aims to build 12 separate
cGMP production modules in a 50,000 sqm facility. Following ICH Q7A
guidelines, these production modules with a total output of approximately
20mt of cGMP intermediate and APIs each year are designed according to
international concepts and are equipped with advanced HVAQ systems. So far,
many intermediates and API's of high value have been manufactured in this
new facility.
In the meantime, a new R&D building with a construction area of 10,000
sqm will be built to allow >300 chemists working at the same time. This new
R&D center, supported with sophisticated analytical instruments will be a
necessary expansion of current R&D and Analytical Research capabilities. It
is expected that the whole construction of Asymchem Life Science will
complete in 2008. As a result, Asymchem's total production value will be of
dynamic value to the pharmaceutical industry.
''Asymchem will be even better positioned to serve foreign
pharmaceutical/biotech customers in a more professional and international
way in the future. We will further increase our capacity in the production
of pharmaceutical intermediates and drug substances and will build
ourselves to a one-stop shop to international pharmas by means of
combination of CMO and CRO,'' stated Dr. Hao Hong, Chairman & CEO of
Asymchem. The operation of new cGMP production facility and R&D center will
turn an important page for Asymchem's investment in China. Advanced
development concept and unparalleled technologies will definitely drive the
domestic industry to better serve international pharmaceutical and biotech
companies.
II. Personnel Training: Asymchem's China Personnel Training Base
Completes as Asymchem's Campus Recruitment grows nationally
On July 29, 2007, Asymchem's China Personnel Training Base is complete
in Dunhua, Jilin province. With a modern design equipped with advanced
multi- media systems, the base allows >60 people to meet together at the
same time. Asymchem envisions this as a place for brainstorming, for
delivery of company concepts and for employee enrichment. In July of 2007,
the 3rd annual Asymchem management meeting was held in the base.
Dr. Hao Hong emphasized, ''Talent development always is the most vital
part of Asymchem development and we always value this part highly.'' The
completion of Asymchem's China Personnel Training Base enhances personnel
training, delivers management concepts and, at the same time, enriches
teamwork spirits.
Oct. 28, Asymchem started its 2008 Campus Recruitment Campaign along
with the presentation on ''Devotion & Development'' nationally. The
campaign includes >20 universities in >9 cities including Chongqing,
Chengdu, Nanjing, Hangzhou, Wuhan, Harbin, Changchun, Lanzhou, Xi'an and
Jinan. The goal is to add 350 new recruits of various levels, including 20
PhDs, 70 masters and 260 bachelors. Student recruitment and presentations
are well received by potential new employees all over the country. As of
Nov. 30, 2007, around 300 fresh students have decided to start their
careers in Asymchem. Moreover, Asymchem is providing ''Asymchem TEDA
Scholarship'' in universities like Sichuan University, Chongqing University
and Lanzhou University to support students who are academically excellent
but financially poor. More than 100 students have received funding from
Asymchem since the beginning of the scholarship. Asymchem believes this
campaign will attract more talented people to participate in the dynamic
growth of the Asymchem organization.
III. More Investment: 1.68 billion RMB Investment in Dagang Established
Asymchem Investment Model in China
Recently, Asymchem has come to an agreement with DEDA, Tianjin for a
project with a total investment of 3 million RMB and a total area of
100,000 sqm. The project, which is the third one of Asymchem in the new
Binhai area aims to produce cGMP intermediate and APIs on large scale
following ICH Q7A guidelines. Recently, Asymchem established Asymchem
Laboratories (Jilin) Co., Ltd in Dunhua, Jilin province, with initial
capital of 240,000,000RMB.
Since 1998, Asymchem has strategically established 6 subsidiaries (3 in
Tianjain, 1 in Fuxin, Liaoning, 1 in Hangzhou, Zhejiang and 1 in Dunhua,
Jilin) in China with its own money. The total investment reaches 1.68
billion RMB. To date, Asymchem has established its own China development
strategy -- headquartered in Tianjin with facilities in both Northeast and
Southern China to involve all business including R&D, process optimization,
manufacturing and product sales.
''Asymchem will surely further its investment in China in the future so
as to much more quickly step into top CRO and CMO industries.'' Dr. Hao
Hong spoke confidently.
参考这条前几天的新闻
凯莱英医药化学公司与大港区签署合作协议
来源:市商务委 发布时间:2007-12-12 09:18:00
日前,凯莱英医药化学公司与天津市大港区签署合作协议,计划投资3亿元人民币在大港开发区设立一家全新的医药工厂,这家工厂是凯莱英公司在天津开发区投资之后又一家新工厂。
新建工厂将于明年年初正式破土动工,投资总额3亿元,注册资金8000万元人民币。新厂占地面积10万平方米,分两期建设完成,项目包括研究分析中心、cGMP标准生产车间、非cGMP标准生产车间、动力供应设施、污水治理及配套设施等。经营范围包括开发、生产、销售合成医药原料及中间体;由基因工程优化的菌种发酵的医药原料生物及酶化学医药原料;研究开发诊断试剂新药技术,并提供相关技术咨询服务。预计2009年底投产。
凯莱英将在大港开发区投建具有世界先进水平的生物医药产业研究中心,确保两年内建成具有百余名高级专业人才的研究中心。同时,投建符合美国FDA审批标准的一流cGMP原料药生产车间。
编者注FDA:Food and Drug Administration(美国)食品及药物管理局
[
本帖最后由 kill_bill 于 2007-12-29 02:18 编辑 ]